Join Dr Charles Pollack for a discussion of his cutting-edge study: Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
Topic
While the preventative properties of NOACs for thrombotic events have been established, many clinicians have expressed reservations for use of NOACs due to the possibility of major bleeding. However, what if a safety net were available, enabling clinicians to administer NOACs more confidently? In this important Journal Club, Dr Charles Pollack will discuss the results of his recent study which show that the effects of the NOAC dabigatran, specifically the possibility of major bleeding, can be wholly and rapidly reversed by the monoclonal antibody idarucizumab.
Target audience
This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in atrial fibrillation management.
Learning objectives
After this activity, participants should be able to:
